JERSEY CITY, N.J., May 1, 2019 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ: SCYX), a biotechnology company delivering innovative
therapies for difficult-to-treat and often life-threatening
infections, today announced that data further demonstrating the
potential for ibrexafungerp to treat VVC will be presented in one
oral and two ePoster presentations at the 2019 American College of
Obstetrics and Gynecology Annual Clinical and Scientific Meeting
(ACOG), May 3-6, 2019 in Nashville, Tennessee.
Ibrexafungerp, the first representative of a novel family of
compounds referred to as "fungerps" (antifungal triterpenoids), is
being developed for oral and intravenous administration and is in
clinical development for the treatment of several serious fungal
infections, including VVC, invasive candidiasis, invasive
aspergillosis and refractory invasive fungal infections, including
Candida auris. Ibrexafungerp is currently in Phase 3
development in VVC.
ACOG, as one of the premier U.S. obstetrics and gynecology
clinical and scientific meetings, brings together experts to
present their latest findings, guidelines and
experiences. Titles and timing of the three ibrexafungerp
presentations are as follows:
Oral Presentation
Title: In Vitro Activity of
Ibrexafungerp (SCY-078) Against Candida spp. (including
Fluconazole-resistant Isolates)
Presenter: Stephen Barat, PhD
Date and Time: Friday, May 3, 10:30 AM CDT
Oral Presentation #: 140P
Session: Oral Presentation M
ePoster Presentations
Title: A Phase 2b,
Dose-Finding Study Evaluating Oral Ibrexafungerp vs Fluconazole in
Vulvovaginal Candidiasis (DOVE)
Presenter: David Angulo, MD
Date and Time: Saturday, May 4, 11:30 AM CDT
Poster Presentation #: 24J
Session: ePoster Session J
Title: Ibrexafungerp, a Novel Oral Antifungal,
Demonstrates No Reproductive or Developmental Harm in Preclinical
Models
Presenter: Christina
Carruthers, PhD
Date and Time: Saturday, May 4, 11:30 AM CDT
Poster Presentation #: 25J
Session: ePoster Session J
The ACOG 2019 presentations will be available on
the SCYNEXIS website following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX)
is a biotechnology company committed to positively impacting the
lives of patients suffering from difficult-to-treat and often
life-threatening infections by developing innovative
therapies. The SCYNEXIS team has extensive experience in
the life sciences industry, having discovered and developed more
than 30 innovative medicines over a broad range of therapeutic
areas. SCYNEXIS's lead product candidate, ibrexafungerp
(formerly known as SCY-078), is a novel IV/oral antifungal agent in
Phase 3 clinical and preclinical development for the treatment of
multiple serious and life-threatening invasive fungal infections
caused by Candida, Aspergillus and
Pneumocystis species. For more information,
visit www.scynexis.com.
Forward Looking Statement
Statements contained in this
press release regarding expected future events or results are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks inherent in SCYNEXIS's ability to
successfully develop and obtain FDA approval for
ibrexafungerp. These and other risks are described more fully
in SCYNEXIS's filings with the Securities and
Exchange Commission, including without limitation, its most recent
Annual Report on Form 10-K under the caption "Risk Factors" and
other documents subsequently filed with or furnished to
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. SCYNEXIS undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
CONTACT:
Investor Relations
Heather
Savelle
Argot Partners
Tel: 212-600-1902
heather@argotpartners.com
Media Relations
George E.
MacDougall
MacDougall
Tel: 781-235-3093
george@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-to-present-data-at-acog-2019-further-demonstrating-the-favorable-profile-of-ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-vvc-300841608.html
SOURCE SCYNEXIS, Inc.